GlassScriptPhysician profile
Jawad Munir
NPI 1851433429
$8,760.03
in general payments reported to CMS, 2019-2025
33 companies · $2,119 in 2025
The $2,119 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $446 · 2021: $643 · 2022: $1,280 · 2023: $1,208 · 2024: $2,140 · 2025: $2,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,303 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,302.95 |
| Education | $163.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,181.82 | 2019-2025 | Tavneos, Aranesp, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $973.95 | 2019-2025 | Farxiga, Lokelma, Flumist Quadrivalent |
| Mallinckrodt Hospital Products INC. | $923.30 | 2020-2025 | Acthar, Terlivaz |
| Aurinia Pharma U.S., INC. | $445.23 | 2021-2025 | Lupkynis |
| Travere Therapeutics, INC. | $431.42 | 2022-2025 | Filspari |
| Vifor Pharma, INC. | $420.38 | 2019-2024 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $409.41 | 2019-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $380.77 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $332.84 | 2019-2025 | Jynarque |
| Daiichi Sankyo INC. | $316.35 | 2019-2025 | Injectafer |
| Novartis Pharmaceuticals Corporation | $276.75 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $274.22 | 2021-2025 | |
| Lilly USA, LLC | $255.08 | 2024-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.97 | 2023-2025 | Jardiance, Cosela |
| Glaxosmithkline, LLC. | $233.94 | 2021-2025 | Benlysta, Arexvy, Shingrix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $212.58 | 2019-2024 | Velphoro, Korsuva |
| Ani Pharmaceuticals, INC. | $201.82 | 2022-2025 | Purified Cortrophin Gel |
| Ardelyx, INC. | $196.13 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $140.53 | 2022-2025 | Gattex |
| Akebia Therapeutics INC | $133.67 | 2020-2025 | Vafseo |
| Janssen Pharmaceuticals, INC | $124.19 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $102.48 | 2023-2025 | |
| Mallinckrodt Enterprises LLC | $89.49 | 2019 | |
| Alexion Pharmaceuticals, INC. | $81.65 | 2019-2023 | Ultomiris |
| Nxstage Medical, INC. | $79.29 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $78.70 | 2020-2024 | Crysvita, Crysvita |
| Amag Pharmaceuticals, INC. | $65.60 | 2021-2022 | |
| Recor Medical INC | $59.23 | 2025 | Paradise Ultrasound Renal Denervation System |
| Corcept Therapeutics | $23.49 | 2025 | Korlym |
| Apellis Pharmaceuticals, INC. | $20.46 | 2025 | Empaveli |
| Scpharmaceuticals INC. | $19.85 | 2025 | |
| Alnylam Pharmaceuticals INC. | $16.33 | 2021 | |
| Janssen Biotech, INC. | $16.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jawad Munir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.